TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Instagram Outage Disrupts Thousands of U.S. Users 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
DALLAS, May 18, 2017 -- TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering, was awarded the title of Most Innovative Small Size Company by the World Textile Information Network (WTiN), publisher of international technical textiles magazine Future Textiles (formerly known as Future Materials).
TissueGen Founder and CSO, Dr. Kevin Nelson, and President and CEO, Christopher Knowles, accepted the award at the Future Textiles Award Gala in Frankfurt, Germany this past week. Organized by WTiN, the third edition of the biennial awards celebrated the best innovations in the technical textiles industry.
TissueGen’s patented process for manufacturing commercially available ELUTE® fiber occurs at or below body temperature thereby preserving the biologic activity of incorporated biologics and pharmaceutical compounds. ELUTE fiber technology enables controlled sustained delivery of a broad range of sensitive biologics and pharmaceuticals directly at the topical application or implant site and may potentially orchestrate and improve the healing process. ELUTE fiber enables tissue engineering and regenerative medicine applications never before possible.
“We are honored to receive this recognition from WTiN as further testament to the groundbreaking work conducted by our scientists at TissueGen,” said Knowles. “We were privileged to participate in this special event and congratulate all the winners and finalists.”
A full list of winners is available here.
About TissueGen
TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen manufactures biodegradable polymer-based fibers with the broadest drug delivery capabilities available today. ELUTE fiber can directly replace standard fibers used in medical devices currently on the market and may provide significantly improved clinical outcomes by delivering sensitive therapeutic agents directly at the implant or topical application site in controlled, sustained release profiles. ELUTE fiber may enable medical device developers to guide the body’s healing and regenerative processes.
For more information, please visit www.tissuegen.com.
For more information contact: Jordan Bouclin SVM Public Relations 401-490-9700 [email protected]
